Laryngeal squamous cell carcinoma · line 1 · EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-EXTREME-HNSCC`

ID	`IND-LARYNGEAL-RM-1L-EXTREME`
Type	Indication
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	`DIS-LARYNGEAL`
Sources	`SRC-EXTREME-VERMORKEN-2008` `SRC-NCCN-HNSCC-2025`

Notes

STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Mirrors IND-HNSCC-RM-1L-EXTREME field-for-field. Reuses REG-EXTREME-HNSCC, DRUG-CETUXIMAB, DRUG-CISPLATIN, DRUG-CARBOPLATIN, DRUG-5-FLUOROURACIL, and the pre-existing SRC-EXTREME-VERMORKEN-2008 unchanged — no new Regimen, Drug, or Source authored for this arm.

Used By

Algorithms

ALGO-LARYNGEAL-1L - ALGO-LARYNGEAL-1L